Analyst downgraded RxSight from Overweight to Underweight and set a new price target of $17.00 from $40.00 previously
Get the next $RXST alert in real time by email
Crush Q3 2025 with the Best AI Executive Assistant
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Recent Analyst Ratings for $RXST
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2025 | $9.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/10/2025 | $9.00 | Buy → Hold | Jefferies |
| 7/9/2025 | Outperform → Perform | Oppenheimer | |
| 7/9/2025 | $9.00 | Overweight → Equal Weight | Wells Fargo |
| 7/9/2025 | Buy → Neutral | BTIG Research | |
| 5/19/2025 | $25.00 | Equal Weight → Overweight | Wells Fargo |
| 4/15/2025 | $18.00 | Neutral | Piper Sandler |
| 4/9/2025 | $16.00 | Buy → Neutral | UBS |
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025, driven by: The
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. RxSight's management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin
RxSight downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded RxSight from Overweight to Equal-Weight and set a new price target of $9.00
RxSight downgraded by Jefferies with a new price target
Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00
RxSight downgraded by Oppenheimer
Oppenheimer downgraded RxSight from Outperform to Perform
Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)
4 - RxSight, Inc. (0001111485) (Issuer)
Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)
4 - RxSight, Inc. (0001111485) (Issuer)
Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)
4 - RxSight, Inc. (0001111485) (Issuer)
Director Link William J Phd was granted 10,752 shares, increasing direct ownership by 40% to 37,855 units (SEC Form 4)
4 - RxSight, Inc. (0001111485) (Issuer)
Director Fountain Tamara was granted 10,752 shares, increasing direct ownership by 43% to 35,545 units (SEC Form 4)
4 - RxSight, Inc. (0001111485) (Issuer)
Director Warner Robert Keith was granted 10,752 shares, increasing direct ownership by 36% to 41,039 units (SEC Form 4)
4 - RxSight, Inc. (0001111485) (Issuer)
RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - RxSight, Inc. (0001111485) (Filer)
RxSight Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - RxSight, Inc. (0001111485) (Filer)
SEC Form SD filed by RxSight Inc.
SD - RxSight, Inc. (0001111485) (Filer)
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors
ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025, driven by: The
RxSight, Inc. Reports First Quarter 2025 Financial Results
ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M
Amendment: SEC Form SC 13G/A filed by RxSight Inc.
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
Amendment: SEC Form SC 13G/A filed by RxSight Inc.
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
Amendment: SEC Form SC 13G/A filed by RxSight Inc.
SC 13G/A - RxSight, Inc. (0001111485) (Subject)